Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

45 results about "Factor H" patented technology

Factor H is a member of the regulators of complement activation family and is a complement control protein. It is a large (155 kilodaltons), soluble glycoprotein that circulates in human plasma (at typical concentrations of 200–300 micrograms per milliliter). Its principal function is to regulate the alternative pathway of the complement system, ensuring that the complement system is directed towards pathogens or other dangerous material and does not damage host tissue. Factor H regulates complement activation on self cells and surfaces by possessing both cofactor activity for the Factor I mediated C3b cleavage, and decay accelerating activity against the alternative pathway C3-convertase, C3bBb. Factor H exerts its protective action on self cells and self surfaces but not on the surfaces of bacteria or viruses. This is thought to be the result of Factor H having the ability to adopt conformations with lower or higher activities as a cofactor for C3 cleavage or decay accelerating activity. The lower activity conformation is the predominant form in solution and is sufficient to control fluid phase amplification. The more active conformation is thought to be induced when Factor H binds to glycosaminoglycans (GAGs) and or sialic acids that are generally present on host cells but not, normally, on pathogen surfaces ensuring that self surfaces are protected whilst complement proceeds unabated on foreign surfaces.

Protein nanostructure vaccine

Provided are protein nanostructures that display Neisseria meningitidis factor H binding protein (fHBP). The protein nanostructure may be a two-component icosahedral nanostructure. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to Neisseria meningitidis.
Owner:ICOSAVAX INC

Neisseria meningitidis compositions and methods thereof

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
Owner:PFIZER INC

Novel group B epidemic cerebrospinal meningitis outer membrane protein bifunctional carrier

The invention discloses a novel group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector, relates to the technical field of biopharmaceutical processes, and discloses a group B epidemic cerebrospinal meningitis outer membrane protein bifunctional vector and application thereof in epidemic cerebrospinal meningitis combined vaccinis.The bifunctional vector is human H factor binding protein fHbp and comprises two recombinant proteins BA and BB, the amino acid sequences of the amino acid sequences are respectively SEQ ID No. 62 and SEQ ID No. 63; the BA protein and the group A capsular polysaccharide are coupled to form a group A conjugate vaccine, the BB protein and the group C capsular polysaccharide are coupled to form a group C conjugate vaccine, the group A conjugate vaccine and the group C conjugate vaccine are mixed to form a group ABC triple vaccine, and each dose of the vaccine contains 40 micrograms of group A polysaccharide and 40 micrograms of group C polysaccharide, 160 micrograms of BA / BB protein and 1.0 mg of aluminum adjuvant; bA and BB proteins are expressed through escherichia coli and are subjected to high-pressure homogeneous crushing and anion exchange chromatography purification, and the purity is greater than or equal to 95%; the triple vaccine provided by the invention can simultaneously induce immune responses to group A, group B and group C meningococcal, the serum sterilization titer after first immunization is greater than or equal to 1: 32, and the titer after three immunization is maintained for more than 56 days.
Owner:BEIJING LUZHU BIOTECH +1

Anti-C5 antibodies fused to factor H for use in the treatment of complement-mediated diseases

The present application provides a method for treating a complement-mediated disease in a human individual, the method comprising administering to the individual an effective amount of a fusion protein comprising: i) an antibody portion that specifically binds to human C5; and ii) factor H (FH) or a functional fragment thereof. The complement-mediated disease can be, for example, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), and thrombotic microangiopathy secondary to systemic lupus erythematosus (SLE-TMA).
Owner:KIRA PHARMACEUTICALS (US) LLC

Meningococcal protein-based vaccine formulations and methods for making same

PendingCN121038809AAntibacterial agentsDepsipeptidesMeningococcal carriageImmunogenicity
The present invention provides fusion proteins having the desire to reduce Factor H binding, in particular the present invention provides optimized processes for the manufacture of fusion proteins and formulations comprising fusion proteins. The present invention provides an effective platform process for the manufacture of an effective vaccine formulation against Neisseria meningitidis, which meets a variety of criteria, including improved immunogenicity, safety, stability, and burdenability.
Owner:SERUM INST OF INDIA PTE LTD

Mutant factor h binding protein (fHbp) of neisseria meningitidis, compositions thereof and uses thereof

The invention relates to biological pharmacy. In particular, the present invention relates to a mutant factor H binding protein (fHbp) of Neisseria meningitidis serogroup B. In addition, the present invention relates to a composition for the prevention of the Factor H binding protein (fHbp) of Neisseria meningitidis. In particular, the present invention relates to mutant factor H binding proteins (fHbp) of Neisseria meningitidis, compositions thereof, and uses thereof. The invention also relates to the use of said mutant factor H binding protein (fHbp) in the treatment or prevention or diagnosis of neisseria meningitidis disease caused by at least one of serogroup A, C, B, Y and W diseases. In particular, the invention relates to a pharmaceutical composition comprising said mutant Factor H binding protein (fHbp) for use in the treatment or prevention or diagnosis of Neisseria meningitidis serogroup B disease.
Owner:TECHINVENTION LIFECARE PRIVATE LIMITED +1

Kidney active fusion proteins and methods of treatment using the same

PCT designated stageWO2026135714A1Connective tissue peptidesPeptide/protein ingredientsSegmental glomerulosclerosisRenal glomerulus
Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.
Owner:ALEXION PHARMACEUTICALS INC

Anti-C5 antibodies fused with factor H for treatment of complement mediated diseases

The present application provides a method of treating a complement-mediated disease in a human subject, the method comprising administering to the subject an effective amount of a fusion protein comprising i) an antibody moiety that specifically binds to human C5 and ii) Factor H (FH) or a functional fragment thereof. The complement-mediated diseases may be, for example, paroxysmal sleep hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), and thrombotic microangiopathy (SLE-TMA) secondary to systemic lupus erythematosus.
Owner:KIRA PHARMACEUTICALS (US) LLC

Compositions and methods for treating complement-mediated diseases

ActiveCN115976105BDiseasePharmacy medicine
The present invention relates to compositions and methods for treating complement-mediated diseases. Provided are recombinant vectors having an expression cassette comprising a modified human factor H (hfH) gene, wherein the hfH gene encodes a hfH protein variant comprising SCR1-4, 19-20, and one or more of: SCR7, SCR17, and / or SCR18. Also provided are pharmaceutical compositions comprising the vectors and their use in treating AMD and / or other complement-related diseases.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Sialylated human factor h protein for treatment of paroxysmal nocturnal hemoglobinuria

PendingAU2025213816A1Paroxysmal AFThrombocyte aggregation
The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.
Owner:ELEVA GMBH

Sialic-acid ligand decorated therapeutics

PendingUS20250186609A1Senses disorderPowder deliveryInfluenza virus CPharmaceutical medicine
The present disclosure provides methods and compositions for modulating the activity of self-associated molecular pattern recognition receptors such as for example, Siglec (sialic-acid-binding immunoglobulin-type lectins) and complement factor H (CFH). Modulating the activity of infectious organisms such as viral influenza A, B, C, SARS-CoV1, 2, and cancer / tumor cells such as lung, breast and skin cancers. The compositions comprise a particle, comprising a molecule represented by the following structural formula:P-L-G,wherein P is a biocompatible polymer scaffold comprising at least one biocompatible polymer defined herein, G is a polysialic acid (PSA) comprising from 5 to 200 repeat units of sialic acid; and L is a covalent linker, or a pharmaceutically acceptable salt thereof.
Owner:AVICEDA THERAPEUTICS INC

Methods of treating ocular diseases using engineered polypeptides comprising complement factor h and factor h-like protein domains

PendingUS20260201001A1DiseaseGeographic atrophy
Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.
Owner:CHARACTER BIOSCIENCES INC

Protein nanostructure vaccine

PCT designated stage expiredWO2025151358A1Antibacterial agentsAntibody mimetics/scaffoldsWAS PROTEINESA Protein
Provided are protein nanostructures that display Neisseria meningitidis factor H binding protein (fHBP). The protein nanostructure may be a two-component icosahedral nanostructure. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to Neisseria meningitidis.
Owner:ICOSAVAX INC

Factor H potentiating antibodies and uses thereof

The invention relates to novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H. The invention further relates to the use of such antibodies and fragments for inhibiting complement activation and treatment of disorders associated with complement activation.
Owner:SANQUIN BLOOD SUPPLY FOUND

Complement factor h related 4-specific antibodies and uses thereof

The present disclosure relates to the treatment and / or prevention of age-related macular degeneration (AMD), including the advanced form of dry AMD referred to as Geographic Atrophy (GA). In particular, the present disclosure provides novel therapeutic antibodies that target components of the alternative pathway of the complement activation system, including complement factor H-related (CFHR) 4.
Owner:BROADWING BIO INC

Modified factor H binding protein

ActiveUS12497432B2Antibacterial agentsDepsipeptidesColonisationVirology
The invention relates to a modified factor H binding protein (fHbp), comprising fHbp, or a variant thereof, modified with the addition of at least one exogenous peptide loop; and associated nucleic acid, compositions, and uses. The invention further relates to treatment or prevention of a pathogenic infection or colonisation of a subject using the modified factor H binding protein (fHbp).
Owner:OXFORD UNIVERSITY INNOVATION LTD

Adjuvanted immunogenic composition against neisseria meningitidis b

PendingUS20260048113A1Antibacterial agentsDepsipeptidesAdjuvantMeningitidis neisseria
The disclosure relates to an immunogenic composition comprising a combination of Neisseria meningitidis serogroup B antigens, said combination comprising at least one factor H binding protein (fHBP) A and at least one factor H binding protein (fHBP) B, and an aluminum hydroxyphosphate (AlPO4) adjuvant, the AlPO4 adjuvant being selected as having a point of zero charge (PZC) below 5.
Owner:SANOFI PASTEUR INC

Group B meningococcus vaccine composition as well as preparation method and application thereof

The invention discloses a group B meningococcus vaccine composition as well as a preparation method and application thereof. The vaccine composition comprises a factor H binding protein (fHbp) fusion protein and an outer membrane vesicle (OMV) wherein the factor H binding protein fusion protein comprises a meningococcal heparin binding protein antigen (NHBA) or a variant thereof, and an operably linked fHbp or a variant thereof. The vaccine composition can induce an organism to generate a functional antibody with bactericidal activity, has bactericidal activity on three variant strains, can induce the organism to generate higher protective response, and improves the bactericidal coverage rate of the vaccine on domestic B group strains.
Owner:SUZHOU JUWEI BIOTECH CO LTD

Biomarkers for preclinical and / or early detection and / or diagnosis of kidney disease

The present invention relates to biomarkers for the preclinical and / or early detection and / or diagnosis of kidney disease. In particular, a combination of at least two proteins selected from the group consisting of collagen type XIII (COLXIII), hyaluronic acid binding protein 2 (HABP2), C4 binding protein (C4BP), complement factor H (CFH), and complement factor I (CFI) is provided for use as a biomarker in a method for preclinical and / or early detection and / or diagnosis of kidney disease. The invention also relates to a method for the preclinical and / or early detection and / or diagnosis of kidney disease, comprising (a) determining the concentrations of at least two proteins in a sample of a subject, and (b) comparing each concentration determined in step (a) to a control value, wherein the deviation of each concentration determined in step (a) from the control value is indicative of a preclinical and / or early kidney disease.
Owner:X KIDNEY DIAGNOSTICS GMBH

Neisseria meningitidis compositions and methods thereof

PendingUS20260124287A1Antibacterial agentsInorganic non-active ingredientsNeisseria meningitidisMeningitides
In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
Owner:PFIZER INC

Engineered complement factor H related protein and application thereof

The invention discloses an engineered complement factor H-related protein and application thereof, the engineered complement factor H-related protein is a polypeptide containing SCR1-2 of a factor H-related protein 1 (FHR1) or a functional fragment thereof, and the polypeptide has a better effect on treatment of complement-related diseases. The invention also discloses a fusion protein containing the polypeptide, or a nucleic acid molecule, a carrier or a cell for coding the polypeptide, and also discloses a pharmaceutical composition and a kit containing the substance.
Owner:PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)

Prophylaxis and therapy for vascular complications of diabetes with immune boosting

Prophylaxis, immune boosting and therapy for vascular complications of diabetes employing various formulations of sulfonic polymers to target and control the activation loop of complement system at C3 level. The molecular targets identified and successfully inhibited are Factor B, Factor D, Factor H. First, this contributes to the inhibition of cross talk pathways in classical and lectin system pathways as well as the C3a and C5a interactions with their receptors. The cross talk pathways inhibit inflammation, oxidative stress, fatty acid synthesis and fibrosis. Secondly, it further inhibits downstream pathways of C5b-9 and also coagulation and thrombotic cascade. Both pathways cause micro vascular and macro vascular complications of diabetes. Thirdly, patient safety is enhanced by Double inhibition of Factor H and Factor D. This reduces adverse effects mediated by individual inhibition of Factor H and Factor D and in addition it has immune boosting effect by targeting immune evasion.
Owner:SHAH KUMARPAL A

AAV variant for the treatment of complement imbalance

PendingJP2026518295AOrganic active ingredientsSenses disorderGeographic atrophyTransgene
Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are a method for delivering the transgene to the retina, and a method for treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration by contacting retinal cells with rAAV. The variant AAV capsid protein may contain a peptide insertion ("heterogeneous peptide" or "peptide insertion") of about 7 to 20 amino acids within the GH loop of the capsid protein, preferably within the surface-exposed region of the GH loop, compared to the corresponding parental AAV capsid protein.
Owner:4D MOLECULAR THERAPEUTICS INC

Sialylated human factor H proteins and therapeutic uses thereof

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragment or biologically active sialylated variant thereof. The invention also relates to methods of producing such proteins in vitro, and methods of using such proteins for the treatment of complement-mediated diseases, such as C3 glomerulopathy, atypical hemolytic uremic syndrome or age-related macular degeneration.
Owner:ELEVA GMBH

Inhibitors of complement factor h

Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
Owner:DUKE UNIV

Factor H vectors and uses thereof

Aspects of the disclosure relate to compositions and methods for expressing a Factor H protein (or a variant thereof) in a cell or subject. In some embodiments, the disclosure provides isolated nucleic acids and rAAVs comprising a transgene encoding a Factor H protein variant and one or more regulatory sequences. In some embodiments, compositions described herein are useful for treating subjects having diseases associated with Factor H deficiency.
Owner:UNIV OF MASSACHUSETTS

Group B meningococcus fusion protein based on iron nanoparticles as well as preparation method and application of group B meningococcus fusion protein

The invention discloses a group B meningococcus fusion protein based on iron nanoparticles as well as a preparation method and application of the group B meningococcus fusion protein. The fusion protein comprises a ferritin subunit or a variant thereof, and an operably linked factor H binding protein (fHbp) or a variant thereof. The fusion protein has good immunogenicity, the immune response level is obviously increased compared with that of an fHbp monomer, and immune response aiming at heterologous or homologous group B meningococcus strains can be initiated. Furthermore, the fusion protein can be used as a candidate antigen of group B meningococcus, and has a very high reference value in the development of group B meningococcus vaccines.
Owner:SUZHOU JUWEI BIOTECH CO LTD

Subcutaneous administration of sialylated human factor h protein

PCT designated stageWO2026087607A1Senses disorderPeptide/protein ingredientsMacula lutea degenerationParoxysmal nocturnal hemoglobinuria
The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof, wherein the protein does not comprise trisia lylated N-glycans of the structure A3G3S3 (NaNaNa), for use in a method of treatment, wherein the method of treatment involves administering subcutaneously said in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof subcutaneously. The methods of treatment comprise treating complement-mediated diseases such as C3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD) or paroxysmal nocturnal hemoglobinuria.
Owner:ELEVA GMBH

Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifically binds to human C5 and ii) a Factor H (FH) or functional fragment thereof. The complement-mediated disease can be, for example, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), and thrombotic microangiopathy secondary to systemic lupus erythematosus (SLE-TMA).
Owner:KIRA PHARMACEUTICALS (US) LLC